Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Browse By Topic
Economics & Value
Economics & Value
Articles about real-world healthcare utilization and costs on Value-Based Cancer Care.
Filter by Topic
Accountable Care Organization
Community Oncology
Comparative Effectiveness
Comparative Effectiveness Research
Economics of Cancer Care
Health Economics
Oncology Benefit Edition
Payer-Provider
Pricing
Reimbursement
Value-Based Care
The Rush to Value
By
William McGivney, PhD
VBCC Perspectives
,
Economics & Value
,
Value-Based Care
July 2015, Vol 6, No 6
The American Society of Clinical Oncology (ASCO) has introduced its conceptual framework to “Assess the Value of Cancer Treatment Options,” with the laudable objective to “assist physicians and patients in assessing the values of a new drug treatment.” As released, the ASCO framework has the potential to confound oncologists, in some instances, as follows.
Read Article
MSKCC and ASCO Cancer Value Calculators
By
Jonathan B. Fassberg, MBA
VBCC Perspectives
,
Economics & Value
,
Value-Based Care
July 2015, Vol 6, No 6
There has been talk regarding pricing in healthcare for a number of years, so the recent move by the American Society of Clinical Oncology (ASCO) and by Memorial Sloan Kettering Cancer Center (MSKCC), discussed in this issue of
Value-Based Cancer Care
, is certainly a big deal, but is hardly surprising.
Read Article
Personalized Medicine Coalition Statement on ASCO’s New Conceptual Framework
By
Edward Abrahams, PhD
VBCC Perspectives
,
Economics & Value
,
Value-Based Care
July 2015, Vol 6, No 6
In the face of escalating costs of cancer drugs, the American Society of Clinical Oncology (ASCO) rightly asks, what is the value of these new medicines?
Read Article
Patient-Centric Cancer Care
By
Rick Lee
VBCC Perspectives
,
Economics & Value
,
Value-Based Care
July 2015, Vol 6, No 6
Rising to a level of equal status with cancer providers is a tall order for patients with cancer, yet it is precisely the intent of the Meaningful Use Stage 3 proposed standards that are set to take effect in 2018 (ie, patient-reported outcomes), as well as the value-based care initiatives. Providers need to drop their resistance and contemplate the following benefits of patient centricity.
Read Article
The ASCO Value Framework: To What End?
ASCO’s Value Framework
,
Value-Based Care
,
VBCC Perspectives
,
Economics & Value
July 2015, Vol 6, No 6
Read Article
ASCO’s Value Framework Abandons the Hippocratic Oath
By
Robert Goldberg, PhD
ASCO’s Value Framework
,
Value-Based Care
,
VBCC Perspectives
,
Economics & Value
July 2015, Vol 6, No 6
The American Society of Clinical Oncology (ASCO) new value framework abandons the Hippocratic Oath. No longer is the doctor’s first obligation to “apply, for the benefit of the sick, all measures which are required.” Instead, ASCO’s value framework has the potential to help insurers “evaluate the relative value of new treatments” as they develop “benefit structures, adjustment of insurance premiums, and implementation of clinical pathways and administrative controls."
Read Article
The New PC-SAF Instrument: A Patient-Reported Outcome Tool for Identifying the Symptoms of Pancreatic Cancer
By
Laura Morgan
Economics & Value
,
Economics of Cancer Care
June 2015, Vol 6, No 5
Philadelphia, PA—The prognosis for patients with pancreatic cancer, the leading cause of cancer-related deaths in the United States, remains poor. The diagnosis of pancreatic cancer is often delayed to a late stage, which affects impact. Improving the understanding of the early signs and symptoms of this cancer may improve outcomes.
Read Article
Increasing Use of Value Analysis Committees in US Hospitals: Implications for Healthcare Providers and Manufacturers
By
Laura Morgan
Economics & Value
,
Economics of Cancer Care
June 2015, Vol 6, No 5
Philadelphia, PA—The growing focus on identifying and preventing overpayments and reducing waste in the healthcare system has prompted hospitals to adopt value analysis committees to curb unnecessary medical supply spending. In 2012, as many as 64% of US hospitals were using a value analysis committee to evaluate new devices and new supplies used in their institutions.
Read Article
Health Plan Cost-Savings with Netupitant/Palonosetron for the Prevention of CINV
By
Laura Morgan
Economics & Value
,
Economics of Cancer Care
May 2015, Vol 6, No 4
San Diego, CA—According to the National Comprehensive Cancer Network guidelines for the prevention of chemotherapy-induced nausea and vomiting (CINV), highly and moderately emetogenic chemotherapy should be managed with a 5-HT3 receptor antagonist, an NK1 receptor antagonist, and dexamethasone (Decadron).
Read Article
Real-World Treatment Patterns of Axitinib for Advanced Renal-Cell Carcinoma
By
Laura Morgan
Economics & Value
,
Economics of Cancer Care
May 2015, Vol 6, No 4
San Diego, CA—Approved in 2012 by the FDA, axitinib (Inlyta) is indicated for the treatment of patients with advanced renal-cell carcinoma (RCC) whose disease had failed 1 previous systemic therapy. The approval of axitinib was based on the safety and efficacy data from clinical trials, which are often limited in their patient population and short-term analysis.
Read Article
Page 7 of 18
2
3
4
5
6
7
8
9
10
11
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma